Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France

BACKGROUND AND AIMS: Lung cancer has the highest mortality rate of all cancers worldwide. Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an extremely poor prognosis. Afatinib is an irreversible ErbB family blocker designed to suppress cellular signaling and inhibit c...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignata, Maud, Chouaid, Christos, Le Lay, Katell, Luciani, Laura, McConnachie, Ceilidh, Gordon, James, Roze, Stéphane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661831/
https://www.ncbi.nlm.nih.gov/pubmed/29123418
http://dx.doi.org/10.2147/CEOR.S136657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661831/
https://www.ncbi.nlm.nih.gov/pubmed/29123418
http://dx.doi.org/10.2147/CEOR.S136657

Ejemplares similares